Ireland has become a key manufacturing centre for the global pharmaceutical market and in turn pharmaceutical manufacturing is now the backbone of the Irish economy. How the industry evolved from small firms that supplied the Irish market only, a sector that was threatened by the introduction of free trade in the 1960s, to becoming a home to most of the world's leading pharma firms over the course of the last fifty years is the theme of this book. It is an Irish success story that has helped to transform Ireland. It tells how inspired leadership, an attractive investment package, and the occasional piece of luck enabled Ireland to opportunistically 'grab the future'. It was not a journey without controversy and confrontation most noticeably on environmental issues. How these disputes were resolved is a key part of this story which concludes with a look at the medium and long-term challenges to the sector.

The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with eighteen chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry.

Originally published in 2012, revised edition published in 2013, by Fourth Estate, Great Britain; Published in the United States in 2012, revised edition also, by Faber and Faber, Inc.

This searing indictment, David Healy’s most comprehensive and forceful argument against the pharmaceuticalization of medicine, tackles problems in health care that are leading to a growing number of deaths and disabilities. Healy, who was the first to draw attention to the now well-publicized suicide-inducing side effects of many anti-depressants, attributes our current state of affairs to three key factors: product rather than process patents on drugs, the classification of certain drugs as prescription-only, and industry-controlled drug trials. These developments have tied the survival of pharmaceutical companies to the development of blockbuster drugs, so that they must overhype benefits and deny real hazards. Healy further explains why these trends have basically ended the possibility of universal health care in the United States and elsewhere around the world. He concludes with suggestions for reform of our currently corrupted evidence-based medical system.

This book provides a cogent summary of the economic history of the Irish Free State/Republic of Ireland. It takes the Irish story from the 1920s right through to the present, providing an excellent case study of one of many European states which obtained independence during and after the First World War. The book covers the transition to protectionism and import substitution between the 1930s and the 1950s and the second major transition to trade liberalisation from the 1960s. In a wider European context, the Irish experience since EEC entry in 1973 was the most extreme European example of the achievement of industrialisation through foreign direct investment. The eager adoption of successive governments in recent decades of a neo-liberal economic model, more particularly de-regulation in banking and construction, has recently led the Republic of Ireland to the most extreme economic crash of any western society since the Great Depression.

-sources of Irish law. --

An accessible and innovative look at Irish history by some of today's most exciting historians of Ireland This book brings together some of today's most exciting scholars of Irish history to chart the pivotal events in the history of modern Ireland while providing fresh perspectives on topics ranging from colonialism and nationalism to political violence, famine, emigration, and feminism. The Princeton History of Modern Ireland takes readers from the Tudor conquest in the sixteenth century to the contemporary boom and bust of the Celtic Tiger, exploring key political developments as well as major social and cultural movements. Contributors describe how the experiences of empire and diaspora have determined Ireland’s position in the wider world and analyze them alongside domestic changes ranging from the Irish language to the economy. They trace the literary and intellectual history of Ireland from Jonathan Swift to Seamus Heaney and look at important shifts in ideology and belief, delving into subjects such as religion, gender, and Fenianism. Presenting the latest cutting-edge scholarship by a new generation of historians of Ireland, The Princeton History of Modern Ireland features narrative chapters on Irish history followed by thematic chapters on key topics. The book highlights the global reach of the Irish experience as well as commonalities shared across Europe, and brings vividly to life an Irish past shaped by conquest, plantation, assimilation, revolution, and partition.

Introduction to Ireland is a fascinating subject that encapsulates all that is beautiful about the Emerald Isle. Ireland, situated in the North Atlantic, is the third-largest island in Europe and the twentieth-largest island globally. Historically, Irish culture has played a significant role in music, literature, and folklore. Ireland is recognized worldwide for its whiskey, beer, and distinctive cuisine. The country boasts of an excellent infrastructure, with several attractions such as breathtaking landscapes, ancient monuments, and urban cities. As a country with a rich history, Ireland is an enchanting place to visit, and tourism is a key driving factor in its economy. Visitors flock the country to explore its many attractions such as the scenic Cliffs of Moher, the awe-inspiring Giant's Causeway, and the historic Trinity College. The Irish are also known for their renowned hospitality and warmth towards tourists. Visitors can enjoy traditional Irish music sessions, explore the many rural towns, and enjoy the local cuisine. In conclusion, an introduction to Ireland is a fantastic opportunity to learn and explore one of the world's hidden treasures.

NEW YORK TIMES BESTSELLER • A NEW YORK TIMES NOTABLE BOOK OF THE YEAR • A grand, devastating portrait of three generations of the Sackler family, famed for their philanthropy, whose fortune was built by Valium and whose reputation was destroyed by OxyContin. From the prize-winning and bestselling author of Say Nothing. "A real-life version of the HBO series Succession with a lethal sting in its tail…a masterful work of narrative reportage.” – Laura Miller, Slate The history of the Sackler dynasty is rife with drama—baroque personal lives; bitter disputes over estates; fistfights in boardrooms; glittering art collections; Machiavellian courtroom maneuvers; and the calculated use of money to burnish reputations and crush the less powerful. The Sackler name has adorned the walls of many storied institutions—Harvard, the Metropolitan Museum of Art, Oxford, the Louvre. They are one of the richest families in the world, but the source of the family fortune was vague—until it emerged that the Sacklers were responsible for making and marketing a blockbuster painkiller that was the catalyst for the opioid crisis. Empire of Pain is the saga of three generations of a single family and the mark they would leave on the world, a tale that moves from the bustling streets of early twentieth-century Brooklyn to the seaside palaces of Greenwich, Connecticut, and Cap d’Antibes to the corridors of power in Washington, D.C. It follows the family’s early success with Valium to the much more potent OxyContin, marketed with a ruthless technique of co-opting doctors, influencing the FDA, downplaying the drug’s addictiveness. Empire of Pain chronicles the multiple investigations of the Sacklers and their company, and the scorched-earth legal tactics that the family has used to evade accountability. A masterpiece of narrative reporting, Empire of Pain is a ferociously compelling portrait of America’s second Gilded Age, a study of impunity among the super-elite and a relentless investigation of the naked greed that built one of the world’s great fortunes.